participate only in the validity study and thirty-nine (39) women will participate in the validity and reliability study. The validity study requires one interview and one salivary sample. The reliability study requires a second interview and a second salivary specimen, approximately two weeks after the first interview.

During the first three months of the study, the Project Director will set up the office, hire staff and student assistants and provide interviewer and data entry training. The Project Director will also make contacts and explore potential sites for recruiting women for the study. During the next nine months, all of the interviews (approximately 115 validity subjects and 39 reliability subjects remaining) will be conducted and data entry of the quantitative instruments (i.e., Demographic Lifestyle Questionnaire, Cohen Perceived Stress Scale, Life Experience Survey (LES), ARIC/BAECKE Questionnaire of Habitual Physical Activity, Center for Epidemiologic Studies Depression Scale (CES–D), Profile of Mood States, Multiple Affect Adjustive Checklist, Speilberger Trait Anxiety Inventory—Self Evaluation Questionnaire) will be completed. Scoring for the qualitative instruments (i.e., Structured Event Probe and Narrative Rating Method (SEPRATE) and Life Events and Difficulties Schedule (LEDS) will be initiated during year 1, but the bulk of the qualitative scoring will be completed during Year 2. The data entry of the qualitative date will be completed during Year 2. Preliminary analyzes will be conducted during Year 2, with the technical assistance of CDC. The total burden hours are 579.

Respondents	No. of respondents	No. of responses/ respondent	Avg. burden/ response (in hrs.)
Reliability Study Group	39	2	3
Validity Study Group	115	1	3

Dated: August 9, 1999.

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation Centers for Disease Control and Prevention (CDC).

[FR Doc. 99–20945 Filed 8–12–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee, Centers for Disease Control and Prevention: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92–463) of October 6, 1972, that the National Vaccine Advisory Committee, Centers for Disease Control and Prevention, of the Department of Health and Human Services, has been renewed for a 2-year period extending through July 30, 2001.

FOR FURTHER INFORMATION CONTACT: Robert F. Breiman, M.D., Executive Secretary, National Vaccine Advisory Committee, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, (A–11), Atlanta, Georgia 30333, telephone 404/639–4452 or fax 404/639–3036.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 9, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention.

[FR Doc. 99–20943 Filed 8–12–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Advisory Committee on HIV and STD Prevention: Meeting

In accordance with section l0(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: CDC Advisory Committee on HIV and STD Prevention.

Time and Date: 8:30 a.m.–5 p.m., September 2, 1999.

Place: Hyatt Regency Atlanta Hotel, Hong Kong Conference Room, 265 Peachtree Street, NE Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available. The meeting room will accommodate approximately 32 people.

Purpose: This Committee is charged with advising the Director, CDC, regarding objectives, strategies, and priorities for HIV and STD prevention efforts including maintaining surveillance of HIV infection, AIDS, and STDs, the epidemiologic and laboratory study of HIV/AIDS and STDs, to prevent the spread of HIV and STDs, and other preventive measures that become available.

Matters to be Discussed: Agenda items include issues pertaining to CDC's HIV Prevention budget. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Paulette Ford, Committee Management Analyst, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E–07, Atlanta, Georgia 30333. Telephone 404/639–8008, fax 404/639–8600, e-mail pbf7@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 9, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 99–20949 Filed 8–12–99; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) Announces the Following Meeting

NAME: Peer Review meeting on the NIOSH research study entitled ''Evaluation of 'Best Practices Back Injury Prevention Program' in Nursing Homes.''

TIME AND DATE: 8:30 a.m.–12 p.m., September 24, 1999.

LOCATION: National Institute for Occupational Safety and Health, Prete Building, Large Conference Room, 3040

University Avenue, Morgantown, West Virginia 26505–2888.

STATUS: Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

PURPOSE: To provide a peer review of the draft research protocol for a study on a back injury prevention program among nursing home workers. Participants will provide NIOSH with comments regarding the technical and scientific aspects of the study protocol, ''Evaluation of a 'Best Practices Back Injury Prevention Program' in Nursing Homes.''

MATTERS TO BE DISCUSSED: The agenda will include a presentation/overview of the study; followed by comments on the technical and scientific aspects of the planned research. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited. Written comments will also be considered.

CONTACT PERSON FOR ADDITIONAL INFORMATION: James W. Collins, Ph.D., Project Officer, Division of Safety Research, NIOSH, CDC, M/S P–1133, 1095 Willowdale Road, Morgantown, West Virginia, 26505–2888. Telephone (304) 285-5998, E-mail joc4@cdc.gov. Copies of the draft protocol may be obtained by contacting Dr. Collins.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: August 9, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office Centers for Disease Control and Prevention.

[FR Doc. 99–20948 Filed 8–12–99; 8:45 am]

BILLING CODE 4160–19–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES–

Food and Drug Administration

[Docket No. 99N–1168]

Public Health Impact of Foodborne Listeria Monocytogenes

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition, in conjunction with the National Advisory Committee on Microbiological Criteria for Foods, in cooperation with the Food Safety and Inspection Service, U.S. Department of Agriculture (FSIS/USDA) is announcing a public meeting to discuss issues related to the risk assessment models under development to examine the relationship between *Listeria monocytogenes* and human health. The sponsoring agencies invite comments on issues related to this meeting.

DATES: The public meeting will be held on Thursday, September 23, 1999, from 8 a.m. to 5 p.m. Submit registration and written notices of participation by September 13, 1999. Submit written comments by October 25, 1999.

ADDRESSES: The public meeting will be held at The Washington Plaza Hotel, 10 Thomas Circle, NW., at Massachusetts Ave. and 14th St., Washington, DC. Submit registration and written notices of participation to Catherine M. DeRoever (address below). Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Catherine M. DeRoever, Advisory Committee Office (HFS–22), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–205–4251, FAX 202–205–4970, or e-mail ''cderoeve@bangate.fda.gov''.

Those persons interested in attending the public meeting should, by September 13, 1999, fax their name, title, firm name, address, and telephone number to Catherine M. DeRoever (fax number above).–

Those persons interested in presenting information at the public meeting should, by September 13, 1999, fax their name, title, firm name, address, telephone number, and an outline of their presentation to Catherine M. DeRoever (fax number above).–

There is no registration fee for this public meeting, but advance registration is suggested. Interested persons are encouraged to register early because space may be limited.

SUPPLEMENTARY INFORMATION: This public meeting will provide an opportunity for an open discussion of the initial calculations of the *L. monocytogenes* risk assessment. The integrating of food groups, *L. monocytogenes* presence in foods and food consumption data will be described and preliminary conclusions drawn. The scientific inferences and models that can be made from the completed search and analysis of epidemiology and dose-response information will be presented. The risk assessment team will request comments on the approaches and analyses presented and on any additional analyses that should be performed.––

The sponsoring agencies encourage individuals with relevant scientific data or information to present such information at the meeting or in written comments to this record.–

A transcript of the public meeting will be prepared. Copies of the transcript may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A–16, Rockville, MD 20857, approximately 15 working days after the meeting.

The transcript of the public meeting and submitted comments will be available for public examination at the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

Dated: August 6, 1999.

Margaret M. Dotzel,

Acting Associate Commissioner for Policy.

[FR Doc. 99–20990 Filed 8–12–99; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES–

Food and Drug Administration

[Docket No. 99N–0438]

Bare-Hand Contact of Ready-to-Eat Foods

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meeting; request for comments.

SUMMARY: The Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition, in conjunction with the National Advisory Committee on Microbiological Criteria for Foods (the committee), and in cooperation with the Food Safety and Inspection Service, U.S. Department of Agriculture is announcing a public meeting to discuss issues related to the contamination of ready-to-eat foods in retail establishments. The sponsoring agencies invite comments on this issue at the request of the Conference for Food Protection.

DATES: The public meeting will be held on Tuesday, September 21, 1999, from 8 a.m. to 5 p.m., and on Wednesday,